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Edited by Vladimir SkulachevAbstract Implantation of a fast growing tumour to mice (Lewis
lung carcinoma) resulted in a clear cachectic state characterized
by a profound muscle wasting. This was accompanied by a signif-
icant increase in both UCP2 and UCP3 gene expression in skel-
etal muscle and heart. Interestingly, this increase in gene
expression was not linked to a rise in circulating fatty acids or
in a decrease in food intake, as previously reported in other path-
ophysiological states. These results question the concept that
hyperlipaemia is the only factor controlling UCP gene expres-
sion in diﬀerent pathophysiological conditions. In addition, the
present work suggests that UCPs might participate in a coun-
ter-regulatory mechanism to lower the production of ROS.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The uncoupling protein-1 (UCP1), present only in brown
adipose tissue (BAT), has been considered to be the only mito-
chondrial protein carrier that stimulated heat production by
dissipating the proton gradient generated during respiration
across the inner mitochondrial membrane, and therefore
uncoupling respiration from ATP synthesis. However, some
years ago, new uncoupling proteins have been described in
mammal tissues. While UCP2 is expressed ubiquitously [1,2],
UCP3 is expressed abundantly and speciﬁcally in skeletal mus-
cle in humans [3] and also in muscle and BAT of rodents [4].
Nowadays, the possible roles of these uncoupling proteins in
thermogenesis and energy balance of intact animals remainAbbreviations: UCP, uncoupling protein; FFA, free fatty acids; ROS,
reactive oxygen species; IL-15, interleukin-15; TNF, tumour necrosis
factor-a; T3, 3,3 0,5-tri-iodo-thyronine; LPS, lipopolysaccharide; IL-1b,
interleukin-1b; NO, nitric oxide; EDL, extensor digitorum longus;
BAT, brown adipose tissue; WAT, white adipose tissue
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doi:10.1016/j.febslet.2004.12.050to be determined. Several factors such as T3 (3,3 0,5-tri-iodo-
thyronine), leptin, lipopolysaccharide (LPS), tumour necrosis
factor-a (TNF), interleukin-1b (IL-1b) and other cytokines in-
crease the UCP2 and UCP3 mRNA levels in animals, suggest-
ing a contribution to thermogenesis [5]. Diﬀerent results
suggest that these proteins could have diﬀerent functions
depending on the metabolic conditions [6–10]. It is well known
that in the course of diﬀerent catabolic states (infection, trau-
ma, tumour growth), there is an increased energy expenditure
[11]. It is therefore interesting to relate this increased energy
expenditure with changes in the level of expression of the dif-
ferent uncoupling proteins which could have a thermoregula-
tory role. Some studies of markers encompassing the human
UCP2/UCP3 locus have revealed a linkage with resting meta-
bolic rate [12], resting energy expenditure [13] and anorexia
nervosa [14]. Other studies suggest that UCP2 and UCP3 are
determinants of basal energy expenditure in humans [15],
whereas no signiﬁcant association between UCP2 and resting
energy expenditure in obese and diabetic humans was detected
[16].
Weight loss, emaciation and progressive alterations of vital
functions are common features associated with the so-called
cancer cachexia. Although in many cases anorexia seems to
be the cause of this syndrome [17], malabsorption or metabolic
changes are often responsible for the weight loss of cachectic
patients [11,18]. During cancer cachexia, the expression of
both UCP2 and UCP3 is upregulated in skeletal muscle [19],
this increase being related to a rise in the circulating levels of
free fatty acids (FFA) [20]. Indeed, we have demonstrated,
using animals bearing the Yoshida AH-130 ascites hepatoma,
that normalization of the increased FFA levels reverts the in-
crease in UCP2 and UCP3 gene expression in skeletal muscle
[20]. In fact, other studies support the hypothesis of the
involvement of UCP2 and UCP3 in the use of FFA [21]. A re-
cent study established also that in a murine model of cachexia
(the MAC16 adenocarcinoma), there was an increase of UCP2
and UCP3 mRNA expression in muscle attributable to a re-
duced food intake and possibly these UCPs are involved in li-
pid utilization [22].
Other functions for the UCP2 and UCP3 have been reported
as a possible role for compensating oxidative stress. In fact,
oxidative stress due to greater levels of reactive oxygen species
(ROS) production than those normally neutralized byblished by Elsevier B.V. All rights reserved.
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attention for its possible involvement in cancer cachexia. Buck
and Chojkier [23] demonstrated that muscle wasting and dedif-
ferentiation could be prevented by inhibitors of nitric oxide
(NO) synthesis and antioxidants. Similarly, Gomes-Marcondes
and Tisdale [24] have shown that muscle wasting in cancer ca-
chexia is associated with increased levels of malondialdehyde
in gastrocnemius muscles, and that mild oxidative stress
increases protein degradation in skeletal muscle by causing
an increased expression of the major components of the ubiq-
uitin-proteasome pathway. In addition, Murr et al. [25] have
shown elevated neopterin (an indicator of ROS production)
concentrations in the serum and urine of cancer patients, this
elevation correlating to the stage of disease, signiﬁcantly
predicting worse prognosis regarding relapse and survival.
Bearing all this in mind, the objective of the present investi-
gation was to examine the expression of both UCP2 and UCP3
in skeletal muscle and heart of tumour-bearing mice and to
establish a relation between their expression and the plasma
FFA levels and the food intake in this particular tumour model,
and their possible role as a mechanism for a compensating oxi-
dative stress.2. Materials and methods
2.1. Animals
C57Bl/6 mice (Criﬀa, Barcelona, Spain) of about 20 weeks of age
were used in diﬀerent experiments. The animals were maintained at
22 C with a regular light–dark cycle (light on from 08:00 a.m. to
08:00 p.m.) and had free access to food and water. The diet (B.K. Uni-
versal G.J./S.L., Sant Vicenc¸ del Horts, Barcelona, Spain) consisted of
45.5–48.5% carbohydrate (3.5% absorbable glucose, 42–45% starch),
18.5% protein and 3.1% fat (the residue was non-digestible material).
Food intake was measured daily. All animal manipulations were made
in accordance with the European Community guidelines for the use of
laboratory animals.
2.2. Tumour inoculation
Two diﬀerent experimental groups were included: control non-tu-
mour-bearing mice and Lewis lung carcinoma-bearing mice 15 days
following tumour inoculation. The tumour-bearing mice group re-
ceived an inoculum of 108 Lewis lung carcinoma cells obtained from
exponential tumours, given intramuscularly (left thigh). On day 15
after tumour transplantation, animals were weighed and anaesthetized
with ketamine/xylazine mixture (i.p.). The tumour was excised from
the hind leg and its mass being determined. Samples of tissues were
rapidly excised, weighed, and frozen in liquid nitrogen. Blood was col-
lected from the abdominal aorta into heparinized tubes and centri-
fuged (3500 · g, 10 min, 4 C) to obtain plasma.2.3. Biochemicals
All enzymes, coenzymes and other chemicals were either obtained
from Roche (Barcelona, Spain) or from Sigma Chemical Co. (St.
Louis, MO, USA). Radiochemicals were obtained from Amersham
(Amersham, Bucks, UK).
2.4. Circulating metabolite analysis
Circulating FFA were determined using the NEFA C kit (Wako
Chemicals, Dallas).
2.5. RNA isolation and Northern blot analysis
Total RNA from skeletal muscle and heart was extracted using the
acid guanidinium isothiocyanate/phenol/chloroform method as de-
scribed by Chomczynski and Sacchi [26]. RNA samples (20 lg) were
denaturated, subjected to 1.2% agarose gel electrophoresis containing
6.3% formaldehyde. The RNA in gels and in ﬁlters was visualized withethidium bromide and photographed by UV transillumination to en-
sure the integrity of RNA, to check the loading of equivalent amounts
of RNA and to conﬁrm proper transfer. RNA was transferred to Hy-
bond N membrane (Amersham) in 20· standard saline citrate (SSC;
0.15 M NaCl and 15 mM sodium citrate, pH 7.0). RNA was ﬁxed to
membrane by Gene Linker (BioRad). Prehybridization was done in a
phosphate buﬀer (250 mM, pH 6.8) containing 7% SDS, 1 mM EDTA
and 1% BSA, during 1 h at 65 C. Membranes were hybridized in the
same buﬀer with appropriate probes (28 Bq/ng) at 65 C for 18 h.
Radiolabelled probes were prepared by the random priming method
(Roche). The probes used were the entire coding frame for mouse
UCP2 [6], a cDNA clone containing the entire coding frame for mouse
UCP3 (D.S. Fleury, C.F. Bouillard, GenBank accession number
AF032902), and a 18S rat ribosomal probe used as hybridization/quan-
tiﬁcation standard. Non-speciﬁcally bound probe was removed by suc-
cessive washes in 2 · SSC + 0.1% SDS (10 min at 65 C), 1·
SSC + 0.1% SDS (10 min at 65 C) and 0.1· SSC + 0.1% SDS
(15 min at 65 C, twice). Speciﬁc hybridization was then detected by
autoradiography in Hyperﬁlm-MP ﬁlm (Amersham) using intensiﬁer
screens for 1–4 days at 80 C. Blots were quantiﬁed on a phosphoim-
ager using the Phoretix 1 D gel analysis (Phoretix Int. Ltd., England).
2.6. RT-PCR
Analysis of mRNA levels for interleukin-15 (IL-15) was performed
with primers designed to detect gene products (Gene Bank Accession
No. BC023698). IL-15 primers are 5 0 TTGCAGTGCATCTCCT-
TACG 3 0 and 5 0 AGCCCAAAATGAAGACATGG 3 0, resulting in
a 443-bp product. 18S was used as a control of loading and the primers
are 5 0 CGCAGAATTCCCACTCCCGACCC 3 0 and 5 0 CCCAA-
GCTCCAACTACGAGC 3 0, resulting in a 212-bp product. RT-PCRs
were performed with 0.4 lg of total RNA by a one-step RT-PCR
method (Ready-to-Go RT-PCR Beads, Amersham Biosciences) as
follows: IL-15: 1· (42 C, 30 min); 1· (92 C, 2 min); 1· (94 C,
1 min); 31· (94 C, 1:30 min; 60 C, 1 min; 72 C, 2 min); 1· (72 C,
4 min). 18S: 1· (42 C, 30 min); 1· (92 C, 2 min); 10· (92 C, 30 s;
55 C, 1 min; 72 C, 2 min); 1· (72 C, 7 min). The RT-PCR products
were electrophoresed in 1.5% agarose gels in TBE buﬀer. The gel was
stained with ethidium bromide and quantiﬁed by scanning densitome-
try. Values for IL-15 mRNA were corrected by 18S RNA expression
and expressed as percentage.2.7. Protein isolation and Western blot analysis
2.7.1. UCP3 Western blot. Mitochondria from gastrocnemius
muscle were isolated in the presence of 1 ml of extraction buﬀer (250
mM sucrose, 1 mM EDTA and 10 mM Tris, pH 7.4), supplemented
with protease inhibitors (Sigma). The mixture was centrifuged at
800 · g for 10 min. The supernatant was centrifuged at 10 000 · g for
10 min and the mitochondrial pellet was resuspended in 25 ll of TES
buﬀer. Mitochondrial protein content was determined according to
the method of Bradford [27]. 15 lg protein was mixed with 3· sample
buﬀer (0.5 M phosphate buﬀer, pH 7.0, 30% [w/v] glycerol, 7.5% [w/v]
SDS, and 0.75 mM Bromophenol blue) and boiled for 3 min and elec-
trophoresed on 12% SDS–PAGE gel. After separation by electrophore-
sis, proteins were transferred to Immobilon PVDF transfer membranes
(Millipore Corporation, Bedford, MA). UCP3 proteins were tagged
with polyclonal antibody recognizing UCP3 (Chemicon International)
at a dilution of 1:1000, followed by a horseradish peroxidase-conju-
gated goat anti-rabbit secondary antibody at a dilution of 1:5000 (Bio-
rad), and detected by enhanced chemiluminescence (ECL detection
system, Amersham). Blots were stripped thereafter and probed with
the rabbit antiserum against cytochrome c (gift of Dr. Costelli, Torino,
Italy). The sizes of proteins were estimated by using protein molecular-
mass standards (Sigma). UCP3 and cytochrome c were quantiﬁed by
scanning densitometry (Phoretix 1D International Ltd, England).
2.7.2. Catalase Western blot. Frozen gastrocnemius muscle sam-
ples were homogenized in a buﬀer containing HEPES 50 mM, 150
mM NaCl, 100 mM NaF, sodium pyrophosphate 10 mM, EDTA 5
mM, glycerol 10%, Triton X-100 0.5%, leupeptin 2 lg/ml; PMSF
100 lg/ml, aprotinin 2 lg/ml and pepstatin A 10 lg/ml (pH 7.2). Sam-
ples were then centrifuged at 1000 · g for 10 min. The pellet was dis-
carded and the supernatant was designated as a crude homogenate.
Total muscle protein level in each sample was determined with the
Bradford technique [27]. Crude muscle homogenates (20 lg per sam-
ple) were boiled for 3 min and electrophoresed on 12% SDS–PAGE
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Immobilon PVDF transfer membranes (Millipore Corporation, Bed-
ford, MA). Membranes were incubated overnight with selective poly-
clonal anti-catalase antibody (Calbiochem Corp., San Diego, CA).
Tissue homogenates obtained from rat erythrocytes were used as posi-
tive control of the catalase. To validate equal protein loading among
various lanes, PVDF membranes were stripped and re-probed with a
monoclonal anti-tubuline antibody (Sigma). Catalase and tubuline
were quantiﬁed by scanning densitometry (Phoretix 1D International
Ltd, England).
2.7.3. Statistical analysis. Statistical analysis of the data was per-
formed by means of the Students t test.3. Results and discussion
Many experiments have been performed in order to eluci-
date the role of the UCPs in adaptative thermogenesis in re-
sponse to cold exposure, but there is some controversy in the
results obtained since some of them indicate an increase of
the mRNA levels whereas others do not observe any changes
[1,7,8]. Several factors such as T3, leptin, LPS, TNF, IL-1b
and other cytokines increase the UCP2 and UCP3 mRNA lev-
els in animals, suggesting a contribution to thermogenesis [28].
In skeletal muscle, UCP3 gene expression is modulated by
food intake, its expression being increased by fasting [29].
These last results are in contradiction with a potential role of
these UCPs (UCP2 and UCP3) in thermogenesis. Indeed, Ric-
quier and Boulliaud [5] have suggested that the UCPs could be
involved in lipid metabolism regulation, and according to Lee
et al. [30], both UCP2 and UCP3 could also have an important
role in the regulation of ROS, which can damage DNA, phos-
pholipids and alter proteins such as transcriptional factors.
As can be seen in Table 1, the implantation of the Lewis lung
tumour resulted in an important decrease in body weight
(31%). Thus, the implantation of the Lewis lung tumour re-
sulted in a decrease in muscle weights (24% for gastrocnemius,
32% for tibialis, 24% for extensor digitorum longus (EDL) and
9% for heart) as we previously reported [31]. This cachectic re-
sponse took place without a signiﬁcant decrease in food intake.Table 1
Food intake, body and tissue weights and circulating fatty acids in
cachectic tumour-bearing mice
Control Tumour-bearing
Initial body weight (g) 24 ± 0.7 (5) 23 ± 0.4 (7)
Final body weight (g) 26 ± 0.7 (5) 18 ± 0.5 (7)***
Food intake (g) 58 ± 2 (5) 57 ± 3 (7)
Tumour weight (g) – 4.3 ± 0.1 (7)
Tissue weights (mg)
Gastrocnemius 596 ± 26 (5) 450 ± 13 (7)***
Tibialis 198 ± 3.5 (5) 134 ± 4.7 (7)***
EDL 41 ± 2 (5) 31 ± 1.2 (7)***
Heart 480 ± 17 (5) 438 ± 6.2 (7)*
WAT (dorsal) 179 ± 11 (5) 16 ± 8 (7)***
WAT (perigenital) 1028 ± 43 (5) 214 ± 92 (7)***
Liver 5286 ± 85 (5) 4926 ± 85 (7)*
Plasma fatty acids (mEq/l) 0.18 ± 0.02 (4) 0.15 ± 0.03 (7)
For full details see Section 2. The results are mean values ± S.E.M. for
the number of animals indicated in parentheses. Final body weight
excludes the tumour. EDL: extensor digitorum longus; WAT: white
adipose tissue. Values that are signiﬁcantly diﬀerent by the Students t
test from the control group are indicated by *P < 0.05, **P < 0.01,
***P < 0.001.Interestingly, tumour burden did not result in an increase in
the circulating concentration of fatty acids as it is observed
in other experimental tumour-bearing models [32].
The expression of the UCPs is presented in Fig. 1. As can be
seen, both UCP2 and UCP3 mRNA content were increased in
skeletal muscle of tumour-bearing mice (6-fold and 3-fold,
respectively). In the cardiac muscle, the expression of the two
genes was also increased (3.8-fold for UCP2 and 1.6-fold for
UCP3). As can be seen in Fig. 2, the implantation of the tu-
mour resulted also in an increase of UCP3 protein content in
gastrocnemius muscle (3.5-fold) in accordance with the in-
creased expression of UCP3 gene.
Interestingly, UCP3 gene expression in skeletal muscle is
increased in those pathophysiological conditions where a
concomitant increase in circulating lipids (FFA in particular)
is observed, such as starvation [10], high-fat diets [1], experi-
mentally induced diabetes [33] and sepsis [34]. A similar
observation has been made in rodent skeletal muscle during
cold-exposure together with a sensitizing of the membrane po-
tential to the uncoupling action of fatty acids, suggesting that
these compounds could have a role during cold-induced ther-
mogenesis [7,8]. In fact, it has been speculated that UCP3
could have a role in lipid metabolism, possibly as a mitochon-
drial fatty acid carrier [35], although some controversy still ex-
ists [36]. On these lines, diﬀerent experiments have shown that
when the circulating FFA concentration is decreased, by
means of hypolipidemic agents, the induction in both UCP2
and UCP3 is abolished [10,20]. In addition, the presence of
fatty acids in C2C12 myotube cultures results in an increase
in UCP3 gene expression [37]. In previous work carried out
in our laboratory, using the Yoshida AH-130 ascites hepatoma
as a cachexia model in the rat, we have reported that both
UCP2 and UCP3 gene expressions are increased in skeletal
muscle [19], and that TNF seems to be partly responsible for
the activation of the transcription of the two genes [38] via
an increased FFA plasma concentration [20]. Thus, we have
shown that the administration of nicotinic acid (a hypolipi-
demic agent) resulted in a downregulation of the UCP3 gene
in soleus muscle, while no changes were observed concerning
UCP2 mRNA content, suggesting a diﬀerential regulation of
the UCP3 gene versus the UCP2 one, since only the former re-
sponded to variation in circulating FFA levels [20]. The results
presented here question the fact that increased UCP3 gene
expression in skeletal muscle is invariably associated with an
elevation of circulating FFA, as mentioned before. The eleva-
tion of both UCP2 and UCP3 mRNA content in skeletal mus-
cle observed in this tumour model is also independent of food
intake, since tumour burden did not induce anorexia (Table 1).
UCPs have also been associated with having a role as a
mechanism for a compensating oxidative stress [28]. Electron
ﬂow through the respiratory chain results in O2 formation
and therefore contributes mostly to the generation of ROS
[39,40]. Conversely, uncoupling the respiratory chain from
oxidative phosphorylation results in less ROS formation.
On these lines, several studies conﬁrm that an increase in
UCP2 gene expression is related to a decreased generation
of H2O2 [41]. In fact, UCP2 induction has been suggested
as a counter-mechanism in pathophysiological conditions
leading to increased oxidative stress. For instance, LPS-trea-
ted rats experience an increase in liver UCP2 mRNA, which
could well represent a compensatory mechanism for ROS
generation [42].
Fig. 1. UCP gene expression in skeletal muscle and heart of cachectic
tumour-bearing mice. (A) Northern blots of gastrocnemius muscle (A)
and heart (B) from control (C) and tumour-bearing mice (TB). The
results of three diﬀerent animals in each group are shown. Expressions
of both UCP2 and UCP3 mRNA were detected after hybridization
with cDNA probes (see Section 2 for full details). (B) Quantiﬁcation of
UCP2 (black) and UCP3 (white) mRNA in gastrocnemius muscle (A)
and heart (B). Autoradiographs were subjected to scanning densitom-
etry. The results are expressed as arbitrary units. (A) UCP2: control
n = 5; tumour-bearing n = 6, (A) UCP3: control n = 4; tumour-bearing
n = 5. (B) UCP2: control n = 5; tumour-bearing n = 7, (B) UCP3:
control n = 5; tumour-bearing n = 6. Values that are signiﬁcantly
diﬀerent by the Students t test from the control group are indicated by
*P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 2. UCP3 protein content in gastrocnemius muscle. (A) Western
blot of mitochondrial extracts of gastrocnemius muscle from control
(C) and tumour-bearing mice (TB). For the Western blot, UCP3
protein was tagged with monoclonal antibodies recognizing UCP3 (for
full details see Section 2). Autoradiographs were subjected to scanning
densitometry. The results of three diﬀerent animals in each group are
shown. (B) Quantiﬁcation of UCP3 protein in gastrocnemius. Control
(C) n = 5; tumour-bearing (TB) n = 5; statistical signiﬁcance of the
diﬀerences: **P < 0.01.
Fig. 3. Catalase protein content in gastrocnemius muscle. (A) Western
blot of crude gastrocnemius muscle homogenates from control (C) and
tumour-bearing mice (TB). For the Western blot, catalase protein was
tagged with selective polyclonal anti-catalase antibody (Calbiochem
Corp., San Diego, CA) (for full details see Section 2). Autoradiographs
were subjected to scanning densitometry. The results of three diﬀerent
animals in each group are shown. (B) Quantiﬁcation of catalase
protein in gastrocnemius. Control (C) n = 5; tumour-bearing (TB)
n = 3; statistical signiﬁcance of the diﬀerences: *P < 0.05.
Fig. 4. IL-15 expression in skeletal muscle and heart of cachectic
tumour-bearing mice. (A) Expression of IL-15 in gastrocnemius muscle
(A) and heart (B) from control (C) and tumour-bearing mice (TB). The
results of two diﬀerent animals in each group are shown. Expressions
of IL-15 mRNA were detected after RT-PCR (see Section 2 for full
details). (B) Quantiﬁcation of IL-15 mRNA in gastrocnemius muscle
(A) and heart (B). RT-PCR electrophoresis was subjected to scanning
densitometry. The results are expressed as arbitrary units. (A) control
n = 10; tumour-bearing n = 8; (B) control n = 4; tumour-bearing n = 6.
Values that are signiﬁcantly diﬀerent by the Students t test from the
control group are indicated by *P < 0.05, ***P < 0.001.
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role of increased expression of both UCP2 and UCP3 of tu-
mour-bearing animals with oxidative stress, we decided to
investigate muscle content of the antioxidant enzyme catalase.
It has been observed that the tumour growth is associated with
an increase of oxidative stress in skeletal muscle [24,43]. As can
be seen in Fig. 3, mice bearing the Lewis lung carcinoma
showed a catalase protein content which was upregulated with
respect to control muscles. We could hypothesize from this
ﬁnding that in this particular experimental cancer cachexia
model, the antioxidant enzyme catalase might partially coun-
teract ROS-mediated eﬀects.IL-15 is an anticatabolic cytokine which exerts important ef-
fects in skeletal muscle [44,45]. Previous work from our labo-
ratory has shown that administration of IL-15 to cachectic
tumour-bearing animals results in an amelioration of the mus-
cle wasting [46]. IL-15 decreases the activity of the ubiquitin/
proteasome pathway (the main proteolytic pathway activated
during cancer cachexia) in skeletal muscle of tumour-bearing
animals [46] and also reverts the increased DNA fragmentation
observed in skeletal muscle of tumour-bearing animals [43].
Recent results from our group indicate that administration
of IL-15 to rats bearing the Yoshida AH-130 ascites hepatoma
induced an increase in the expression of UCP2 and UCP3 in
skeletal muscle, where an increase in skeletal muscle oxidative
stress has been observed [43]. We therefore put forward the
idea that the cytokine could exert its eﬀects by decreasing oxi-
dative stress, possibly by inﬂuencing the content (and activity)
of UCPs in skeletal muscle. Taking all this into consideration,
we decided to analyze the IL-15 expression in the skeletal mus-
cle and heart where the upregulation of UCP2 and UCP3 has
been shown (Fig. 4). Interestingly, in the tissues analyzed there
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cytokine could have a role in the upregulation of UCPs pro-
teins in tumour-bearing animals. However, further research
is necessary to elucidate the mechanism(s) that underlie the
regulation of UCPs gene expression in pathological states such
as cancer cachexia.
In conclusion, the results presented here clearly show that
activation of UCPs in skeletal muscle is not unequivocally
linked with lipid oxidation as previously suggested. Our results
during cancer cachexia clearly show that neither anorexia nor
high circulating FFA concentrations seem to be linked with
UCP gene activation in this tumour model. The upregulation
of the UCPs genes seems to correlate with a clear antioxidative
capacity, lowering the content of ROS, this phenomenon pos-
sibly being linked by the muscle anabolic cytokine IL-15.
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